Pharmaceutical giant AbbVie announced the acquisition of Gilgamesh Pharmaceuticals’ investigational psychedelic drug bretisilocin for up to $1.2 billion, including upfront and milestone payments. The compound, currently in Phase II trials for major depressive disorder, represents AbbVie's expanding focus in neuroscience and psychedelic therapeutics. Gilgamesh will spin out a new entity to pursue other drug programs, continuing its focus on neuroplasticity-targeted treatments. This deal follows prior collaboration agreements and highlights growing pharma interest in psychedelic modalities for psychiatric indications.